bullish
Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated
A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
ANTYA Investments
Investing That Empowers You
- Tesla Motors – Gaining Industrial Strength31 Jan 2019
- Bristol-Myers Beats the Drum for Celgene in 4Q18 Earnings Call25 Jan 2019
- Bristol Myers Squib – Reaffirming Its View on Celgene Corp25 Jan 2019
- Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated18 Jan 2019
- Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs13 Jan 2019
- We Are Buying This Large Cap Biotechnology Company After Trump's Election Win11 Nov 2016
x